## **1 ELECTRONIC SUPPLEMENTARY INFORMATION**

## 2 Microparticles Formulated from a Family of Novel Silylated Polysaccharides

## 3 Demonstrate Inherent Immunostimulatory Properties and Tunable Hydrolytic

## 4 Degradability

- 5 Matthew D. Gallovic,<sup>1,2,†</sup> Saibal Bandyopadhyay,<sup>3,†</sup> Hassan Borteh,<sup>3</sup> Douglas G. Montjoy,<sup>1</sup>
- 6 Michael A. Collier,<sup>2</sup> Kevin J. Peine,<sup>2</sup> Barbara E. Wyslouzil,<sup>1,4</sup> Eric M. Bachelder,<sup>2</sup> Kristy M.

7 Ainslie<sup>2,\*</sup>

- 8 <sup>1</sup>William G. Lowrie Department of Chemical and Biomolecular Engineering, College of
- 9 Engineering, The Ohio State University, Columbus, OH 43210
- $10^{-2}\mbox{Division}$  of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North
- 11 Carolina, Chapel Hill, NC 27599
- 12 <sup>3</sup>Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State
- 13 University, Columbus, OH 43210
- <sup>14</sup> <sup>4</sup>Department of Chemistry and Biochemistry, College of Arts and Sciences, The Ohio State
- 15 University, Columbus, OH 43210
- $16~\,^{\rm t}{\rm M.D.G.}$  and S.B. should be considered equal first authors.
- 17
- 18 Corresponding Author.
- 19 \*Kristy M. Ainslie, PhD
- 20 Associate Professor, UNC Eshelman School of Pharmacy
- 21 Division of Molecular Pharmaceutics
- 22 Chapel Hill, NC 27599
- 23 Email: ainsliek@email.unc.edu



2 Figure S1. Size exclusion chromatogram of trimethylsilyl dextran with 98% extent of silylation,

3 TMS-DEX(98%), demonstrates no degradation of the 71 kDa dextran starting material.



- 2 Figure S2. <sup>1</sup>H nuclear magnetic resonance spectra of (A) TMS-DEX(59%), (B) TMS-DEX(98%),
- 3 (C) EDMS-DEX(40%), and (D) TES-DEX(57%) polymers dissolved in deuterated chloroform.
- 4 Refer to Table 2 for definitions of polymer abbreviations.





3 TMS-DEX(59%), (B) TMS-DEX(98%), (C) EDMS-DEX(40%), and (D) TES-DEX(57%). Refer to

4 Table 2 for definitions of polymer abbreviations.



- 2 Figure S4. Representative scanning electron micrograph of homogenized microparticles. Scale
- 3 bar = 5 μm.
- 4



1

2 Figure S5. (A) Total anti-ovalbumin (anti-OVA) IgG antibody titers (ng/mL) in mouse sera

3 collected at Day 13 and 28. Data are presented as  $log_{10}$ -transformed with the mean + 95%

4 confidence intervals (n = 4). Statistical comparisons are presented between all OVA groups for

5 (B) Day 13 and (C) Day 28. Statistical indicators are as follows: \*\*\* p < 0.001, \*\*\*\* p < 0.0001,

6 and n.s. = not significant. All OVA groups also are statistically greater than PBS and Blank MPs.

7 N/A = not applicable. Refer to Table 1 for definitions of immunization group abbreviations. The

8 PBS, OVA, and OVA + Alum data were previously published in reference 43.

1 Table S1. Anti-ovalbumin (Anti-OVA) IgG1 and IgG2a antibody titers (ng/mL) in mouse sera

2								colle
3		PBS	Blank MPs	OVA	OVA + Blank MPs	OVA-Loaded MPs	OVA + Alum	cted
4	lgG1	N/D	N/D	4.5 ± 0.2 #	5.0 ± 0.2 <sup>#,†</sup>	5.4 ± 0.2 <sup>#,†</sup>	5.7 ± 0.1 <sup>#,†,‡</sup>	at
5	lgG2a*	N/D	N/D	1.6	N/D	2.7, 1.9, & 1.7	N/D	Day
6	42.	I	l			l		1

7

, ,

8 N/D = titers not detected

9 #All mice (n = 4) generated titers. Data are displayed as mean ± standard error mean and

10 presented after  $log_{10}$ -transformation.

11 <sup>†</sup>Statistically significant compared to OVA (p < 0.01 for OVA + Blank MPs;

12 p < 0.0001 for OVA-Loaded MPs and OVA + Alum)

13 \*Statistically significant compared to OVA + Blank MPs (p < 0.001)

14 \*Listed titers are individual replicates and are presented after log<sub>10</sub>-transformation.

15 Refer to Table 1 for definitions of immunization group abbreviations.